Aarti Pharmalabs Limited has informed the Exchange about Transcript
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarti Pharmalabs reported Q1 FY26 standalone revenue of Rs. 375 crores (down from Rs. 394 crores YoY), with EBITDA growing 14% YoY to Rs. 95 crores and PAT up 9% to Rs. 51 crores. Consolidated revenue fell sharply to Rs. 386 crores from Rs. 555 crores because joint venture Ganesh Polychem (GPL) is now consolidated via the equity method rather than line by line. The decline in standalone topline is partly attributed to a Rs. 15-20 crore hit from extended plant shutdown at one Xanthine site, plus shipping space constraints in API exports. CDMO contributes 10% of revenue with 21 customers and 60 active projects (33 commercial, 27 in development), and management reiterated 35-40% CDMO growth guidance for FY26. Brownfield Xanthine expansion (5000 to 9000 MT) and greenfield Atali project are on track for H2 FY26 commissioning, with multi-year targets of Rs. 1,000 crores+ in Xanthine and Rs. 800-1,000 crores in CDMO over the next 3-4 years.
Short-term revenue optics are weak due to plant shutdown and GPL accounting change, but EBITDA growth and margin stability on a standalone basis signal operational resilience. Capacity additions in H2 FY26 and CDMO ramp-up are the key forward catalysts, while low US exposure (8-10%) limits tariff risk for shareholders.